19 Feb 2018
NICE Approves Cabozantinib for Metastatic MTC
Cabozantinib is now recommended as an option for treating medullary thyroid cancer (MTC) that cannot be operated on or has spread around the body. MTC is a rare type of thyroid cancer with around 80 people diagnosed with it each year in England. Cabozantinib is a targeted therapy which works by blocking certain proteins on cancer cells, stopping them growing and dividing. It is estimated from the clinical trial data, that the drug gives patients an extra 5.5 months of life by slowing down the growth of the disease. AMEND is grateful that NICE and Ipsen could work together to make this recommendation come to fruition, and thanks all those patients who gave us their input for the Appraisal process.